1800-272-662
Shopping Cart 0
countryflagAU
Login

Memphasys Ltd

Healthcare AU MEM

0.005AUD
-0.001(16.67%)

Last update at 2026-03-13T01:26:00Z

Day Range

0.0050.005
LowHigh

52 Week Range

0.0030.01
LowHigh

Fundamentals

  • Previous Close 0.006
  • Market Cap17.08M
  • Volume190000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.44747M
  • Revenue TTM0.21M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.13M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -4.94191M -4.44202M -3.40262M -2.08196M -1.48643M
Minority interest - - - - -
Net income -4.94191M -4.44202M -3.40262M -2.08196M -1.48643M
Selling general administrative 0.86M 1.25M 0.58M 1.09M 1.24M
Selling and marketing expenses 0.09M 0.11M 0.15M 0.11M -
Gross profit 0.43M -1.56821M 0.00922M 0.00824M 0.00824M
Reconciled depreciation - 0.72M 0.61M 0.12M 0.26M
Ebit -3.23182M -4.95419M -3.08584M -1.62931M -1.46109M
Ebitda -2.56551M -4.23703M -2.47300M -1.50609M -1.20161M
Depreciation and amortization 0.67M 0.72M 0.61M 0.12M 0.26M
Non operating income net other - - - - -
Operating income -2.56551M -5.23873M -2.76149M -1.96653M -1.46109M
Other operating expenses 3.09M 5.30M 3.60M 2.05M 1.96M
Interest expense 0.59M 0.42M 0.32M 0.45M 0.03M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.58M 0.31M 0.39M 0.00071M 0.00254M
Net interest income - -0.41713M -0.41494M -0.56597M -0.08697M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.00000M 0.96M 1.67M 0.33M
Total revenue 0.53M 0.06M 0.02M 0.03M 0.03M
Total operating expenses 3.00M 3.68M 3.64M 2.74M 1.96M
Cost of revenue 0.10M 1.63M 0.00615M 0.02M 0.02M
Total other income expense net -2.37640M 0.80M 0.65M 1.22M 0.30M
Discontinued operations - - - - -
Net income from continuing ops - -4.44202M -3.40262M -2.08196M -1.48643M
Net income applicable to common shares -5.03908M -4.44202M -3.40262M -2.08196M -1.48643M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 11.02M 12.43M 14.67M 14.12M 14.58M
Intangible assets 9.11M - 10.29M 9.68M 8.29M
Earning assets - - - - -
Other current assets 0.08M 1.18M 1.36M 1.55M 1.57M
Total liab 5.65M 5.59M 7.28M 6.47M 5.97M
Total stockholder equity 5.37M 6.84M 7.38M 7.65M 8.61M
Deferred long term liab - - - - -
Other current liab 0.26M 0.24M 5.45M 4.41M 0.70M
Common stock 60.61M 57.28M 53.42M 50.34M 48.88M
Capital stock - - 53.42M 50.34M 48.88M
Retained earnings -55.24760M -50.43009M -46.17323M -42.77061M -41.16742M
Other liab - - 0.00136M 0.03M 0.03M
Good will - - - - -
Other assets - - - - -
Cash 0.30M 0.28M 0.64M 0.27M 2.00M
Cash and equivalents - - - - -
Total current liabilities 5.38M 5.25M 5.57M 4.54M 0.86M
Current deferred revenue - 0.07M -4.65768M -3.65939M -0.26886M
Net debt 4.81M 4.48M 5.73M 5.29M 3.35M
Short term debt 4.83M 4.42M 4.66M 3.66M 0.27M
Short long term debt - - 4.55M 3.56M 0.18M
Short long term debt total 5.11M 4.76M 6.37M 5.56M 5.36M
Other stockholder equity - -0.01245M -7.24456M -7.57033M -7.71675M
Property plant equipment - - 2.10M 2.34M 2.60M
Total current assets 1.33M 1.62M 2.25M 2.03M 3.69M
Long term investments - - 0.03M 0.07M -
Net tangible assets - - -2.91005M -2.03224M 0.32M
Short term investments - - 0.04M - -
Net receivables 0.90M - 0.12M 0.12M 0.01M
Long term debt - - - 0.08M 3.16M
Inventory 0.06M 0.16M 0.13M 0.09M 0.12M
Accounts payable 0.28M 0.52M 0.12M 0.13M 0.16M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00246M - 0.14M 0.08M 0.89M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 10.09M -12.41911M -12.09258M -10.89206M
Deferred long term asset charges - - - - -
Non current assets total 9.69M 10.81M 12.42M 12.09M 10.89M
Capital lease obligations - - 1.83M 1.92M 2.01M
Long term debt total - - 1.71M 1.83M 4.86M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -0.71105M -1.97670M -3.07778M -3.00155M
Change to liabilities - - -0.00426M 1.89M 1.41M
Total cashflows from investing activities -0.67328M -0.71105M -1.97670M -3.07778M -3.00155M
Net borrowings - 0.29M 0.68M -0.01317M 2.81M
Total cash from financing activities 3.15M 3.54M 3.75M 1.03M 2.99M
Change to operating activities - - 1.93M 0.86M 0.09M
Net income -4.94191M -4.44202M -3.40262M -2.08196M -1.48643M
Change in cash 0.06M -0.40278M 0.37M -1.73384M 0.04M
Begin period cash flow 0.24M 0.64M 0.27M 2.00M 1.97M
End period cash flow 0.30M 0.24M 0.64M 0.27M 2.00M
Total cash from operating activities -2.40978M -3.23137M -1.40667M -0.36885M 0.04M
Issuance of capital stock - 3.72M 3.36M 1.08M 0.19M
Depreciation 0.67M 0.72M 0.12M 0.12M 0.26M
Other cashflows from investing activities -0.67328M -0.07733M -0.15467M -0.15467M 0.00254M
Dividends paid - - 0.85M 0.07M 2.97M
Change to inventory 0.11M -0.03397M -0.04370M 0.03M -0.08612M
Change to account receivables -0.00669M 0.65M - - -
Sale purchase of stock 3.73M -0.36797M -0.28357M -0.03053M -0.00613M
Other cashflows from financing activities -0.15680M -0.10284M 1.60M -0.01317M 5.84M
Change to netincome - - -0.49708M -0.54806M -0.14158M
Capital expenditures 0.00000M 0.64M 1.82M 2.92M 3.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.91M 1.65M -0.04370M 0.03M -0.08612M
Stock based compensation - 0.04M 0.09M 0.07M 0.14M
Other non cash items 0.96M -1.19822M 1.88M 1.59M 1.27M
Free cash flow -2.40978M -3.86963M -3.22870M -3.29197M -2.95939M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MEM
Memphasys Ltd		 -0.001 16.67% 0.005 - - 79.84 1.67 1696.20 -11.1564
COH
Cochlear Ltd		 -4.74 2.65% 174.42 33.10 26.39 4.88 6.04 5.59 23.13
4DX
4DMEDICAL Ltd		 -0.15 3.55% 4.07 - - 401.92 37.59 417.71 -7.2899
AVR
Anteris Technologies Global Corp		 - -% 9.10 - - 475.96 166.77 334.65 -5.1986
PNV
Polynovo Ltd		 - -% 0.94 94.00 30.21 4.66 7.81 4.68 93.96

Reports Covered

Stock Research & News

View All

Profile

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.

Memphasys Ltd

34-36 Richmond Road, Homebush, NSW, Australia, 2140

Key Executives

Name Title Year Born
Ms. Alison Mary Coutts B.E., B.E. (Chem), GDipBiotech, M.B.A., MBA MD, CEO & Director NA
Pablo Neyertz Director of Fin. NA
Nick Gorring Operations Mang. NA
Mr. Malcolm Coleman Chief Financial Officer of Nusep Ltd NA
Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD Company Sec. NA
Dr. David Ali Acting CEO & Executive Director NA
Pablo Neyertz Director of Finance NA
Associate Prof. Hassan Bakos Director of Operations NA
Prof. R. John Aitken Ph.D., ScD FRSE Scientific Director NA
Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.